Featured
-
-
Article
| Open Access
A vaccine targeting mutant IDH1 in newly diagnosed glioma
A phase 1 clinical trial provides evidence that a vaccine against mutant IDH1 is safe and produces a T helper immune response in patients with glioma.
- Michael Platten
- , Lukas Bunse
- & Wolfgang Wick
-
Article |
Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection
An antibody Fc domain variant with enhanced binding to an activating Fc receptor on dendritic cells promotes the induction of a protective CD8 T cell response.
- Stylianos Bournazos
- , Davide Corti
- & Jeffrey V. Ravetch
-
Article |
A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity
A recombinant vaccine that targets the receptor-binding domain of the spike protein of SARS-CoV-2 induces a potent antibody response in immunized mice, rabbits and non-human primates, and protects primates from infection with the virus.
- Jingyun Yang
- , Wei Wang
- & Xiawei Wei
-
Article |
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
Results of an exploratory interim analysis from a phase I trial show that an RNA vaccine targeted towards four melanoma-associated antigens produces durable objective responses in patients with melanoma that are accompanied by strong CD4+ and CD8+ T-cell immunity.
- Ugur Sahin
- , Petra Oehm
- & Özlem Türeci
-
Article |
Dynamics and genomic landscape of CD8+ T cells undergoing hepatic priming
CD8+ T cells that are primed by hepatocytes differentiate into dysfunctional T cells, which can be rescued by treatment with IL-2.
- Alexandre P. Bénéchet
- , Giorgia De Simone
- & Matteo Iannacone
-
Letter |
Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumours
The transcription factor Runx3 is identified as a central regulator of the development of tissue-resident memory CD8+ T cells, providing insights into the signals that promote T cell residency in non-lymphoid tissues and tumours.
- J. Justin Milner
- , Clara Toma
- & Ananda W. Goldrath
-
Letter |
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
The authors report the first-in-human application of personalized neo-antigen RNA vaccines in patients with melanoma.
- Ugur Sahin
- , Evelyna Derhovanessian
- & Özlem Türeci
-
Letter |
Tumour ischaemia by interferon-γ resembles physiological blood vessel regression
Interferon-γ acts on tumour endothelial cells to drive vascular regression, inducing ischaemia that leads to tumour collapse.
- Thomas Kammertoens
- , Christian Friese
- & Thomas Blankenstein
-
Letter |
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
The development of a nanoparticle RNA vaccine is reported that preferentially targets dendritic cells after systemic administration, and is shown to provide durable interferon-α-dependent antigen-specific immunity in mouse tumour models; initial results in advanced melanoma patients indicate potential efficacy in humans.
- Lena M. Kranz
- , Mustafa Diken
- & Ugur Sahin
-
Letter |
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
The authors show that a large fraction of tumour mutations is immunogenic and predominantly recognized by CD4+ T cells; they use these data to design synthetic messenger-RNA-based vaccines specific against tumour mutations, and show that these can reject tumours in mice.
- Sebastian Kreiter
- , Mathias Vormehr
- & Ugur Sahin
-
Letter |
Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients
A clinical trial in patients with glioblastoma shows increased immune and anti-tumour responses to dendritic cell vaccination after pre-conditioning the site of vaccination with tetanus toxoid (Td); similar results are also seen in mice in part due to the actions of the chemokine CCL3, and the findings may represent new ways to improve the efficacy of anti-cancer vaccines.
- Duane A. Mitchell
- , Kristen A. Batich
- & John H. Sampson
-
Outlook |
The age of vaccines
The advent of routine childhood vaccination has led to dramatic declines in many contagious diseases in the United States. Maintaining these gains there and spreading these successes worldwide are major public-health challenges. By Tony Scully.
- Tony Scully
-
Outlook |
Production: Vaccines from the East
China is poised to become a major global vaccine maker, but first it must overcome serious problems with quality control.
- Priya Shetty
-
Outlook |
Polio: The eradication endgame
Researchers are developing a strategy that could put an end to polio forever.
- Cassandra Willyard
-
Outlook |
Logistics: Keeping cool
Extreme temperatures damage vaccines. Efforts are underway to find better ways to deliver the goods.
- Neil Savage
-
Outlook |
Perspective: Elimination round
We must push harder to eliminate diseases, for everyone's benefit, say Andrew Artenstein and Gregory Poland.
- Andrew W. Artenstein
- & Gregory A. Poland
-
Outlook |
Perspective: Ill prepared for a pandemic
Klaus Stöhr asks whether those responsible for public health will grasp new opportunities to ensure pandemic vaccine readiness.
- Klaus Stöhr
-
Outlook |
Public health: An injection of trust
Faced with outbreaks of preventable diseases, public-health experts need to win over parents who refuse vaccinations.
- Michael Eisenstein
-
News |
Polio campaign at turning point, after Pakistan killings
Vaccination will go on despite setback, say eradication campaigners.
- Ewen Callaway
-
Letter |
A vaccine strategy that protects against genital herpes by establishing local memory T cells
A genital herpes simplex vaccine strategy of immunization using attenuated virus with peripheral local chemokine application can establish a population of protective tissue-resident memory T cells.
- Haina Shin
- & Akiko Iwasaki
-
News |
US states make opting out of vaccinations harder
Legislative efforts aim to tackle rising incidence of disease.
- Tara Haelle
-
News |
HIV vaccine trials struggle to enrol women
Lack of testing could make potential HIV vaccine less effective for women, say researchers.
- Esther Nakkazi
-
News |
Vaccine trial reveals chinks in HIV's armour
Analysis identifies target for immune response that could improve AIDS vaccines.
- Ewen Callaway
-
Outlook |
Perspective: Vaccinate boys too
HPV-associated cancers in men are on the rise. By not vaccinating boys we are failing to gain maximum health benefit, argues Margaret Stanley.
- Margaret Stanley
-
Outlook |
Public health: Prevention comes of age
Sub-Saharan countries lag behind in screening and treatment for human papillomavirus. But national efforts and the introduction of low-tech methods could change that.
- Michael Eisenstein
-
Editorial |
A war not yet won
The eradication of polio is within reach, but it is too early for self-congratulation.
-
News |
Polio’s last stand
As the global eradication effort ramps up, funding shortfalls threaten the programme’s gains in Africa and Asia.
- Ewen Callaway
-
News |
Manufacturing chemicals may damage the immune system
Childhood exposure to perfluorinated compounds linked to reduced effectiveness of tetanus and diphtheria vaccines.
- Daniel Cressey
-
News |
India on track to be declared polio-free next month
The polio virus has disappeared from the country for 12 months, but it could still be re-imported from neighboring nations.
- Helen Branswell
-
News |
Failed herpes vaccine puzzles virologists
Researchers go back to basics in search for new approach to overcoming genital herpes.
- Heidi Ledford
-
Letter |
Antibody-based protection against HIV infection by vectored immunoprophylaxis
A single injection of a viral vector that encodes antibodies able to neutralize most HIV strains protects humanized mice from HIV infection.
- Alejandro B. Balazs
- , Joyce Chen
- & David Baltimore
-
News |
Vaccine campaign to target deadly childhood diarrhoea
Programme to guard against second-biggest killer of under-fives rolls out across Africa.
- Declan Butler
-
News |
Fake vaccination campaign raises real fears
Alleged CIA ruse riles Pakistani researchers.
- Geoff Brumfiel
-
Letter |
A genetically humanized mouse model for hepatitis C virus infection
- Marcus Dorner
- , Joshua A. Horwitz
- & Alexander Ploss
-
Comment |
Target the fence-sitters
Past waves of vaccine rejection in industrialized nations have a lot to teach us about preventing future ones, argues Julie Leask.
- Julie Leask
-
News Feature |
Vaccines: The case of measles
Vaccination campaigns against measles have had dramatic results — but eradicating the disease is still a distant prospect.
-
News |
Vaccination would curb Haitian cholera
Targeting limited doses on those most at risk could save thousand of lives, say researchers.
- Vicki Brower
-
Comment |
Vaccinate for the next H2N2 pandemic now
An old influenza strain still circulating in birds and swine could easily jump back to humans now that immunity to it has dropped, warn Gary J. Nabel and his colleagues.
- Gary J. Nabel
- , Chih-Jen Wei
- & Julie E. Ledgerwood
-
Letter |
Programming the magnitude and persistence of antibody responses with innate immunity
Here it is shown that nanoparticles containing two Toll-like receptor ligands can boost the magnitude and persistence of vaccine-elicited antibody responses in primates, improving vaccine-mediated protection against influenza virus.
- Sudhir Pai Kasturi
- , Ioanna Skountzou
- & Bali Pulendran
-
News Explainer |
A last push to eradicate polio
Funding gap persists as agencies and organizations attempt to wipe out the tenacious virus.
- Gayathri Vaidyanathan
-
News |
Exposure to seasonal flu weakened armour against H1N1
Faulty antibodies from previous infections boosted severity of swine flu in the middle-aged.
- Janelle Weaver
-
Correspondence |
Questioning the timeline of H1N1 flu vaccination contracts
- Deborah Cohen
- & Philip Carter
-
Opinion |
Vaccinate before the next pandemic?
Klaus Stöhr of Novartis argues that pre-pandemic immunization with a cocktail of likely strains could be a cheap, practical and equitable way to protect people against influenza.
- Klaus Stöhr
-
News |
Cash crisis looms for vaccine drive
Rising demand for immunization programmes in developing countries could outstrip funding.
- Declan Butler
-
News |
Ten billion dollars pledged for 'decade of vaccines'
Gates Foundation cash could save nearly nine million children.
- Heidi Ledford
Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice